Embrace scar therapy: Clinical guide and aftercare instructions

Key Takeaways

Embrace scar therapy is an FDA-cleared medical device using tension-offloading technology to prevent hypertrophic scar formation after surgery.

Active Scar Defense is designed for new scars (2-4 weeks post-op). Minimize is for established scars with weaker clinical evidence.

A published RCT measured scar appearance using the Visual Analogue Scale (VAS, its primary endpoint) and the Patient and Observer Scar Assessment Scale (POSAS, its secondary endpoint), showing statistically significant improvement versus standard care.

Pabau’s client portal and digital forms enable practices to distribute branded Embrace aftercare instructions and track scar outcomes systematically.

Clinicians and post-surgical care teams use digital forms to send branded Embrace scar therapy aftercare instructions to patients within hours of surgery, ensuring consistent education and improving compliance.

This guide explains the clinical rationale, application protocol, and outcome-tracking framework for integrating Embrace into your practice.

What is Embrace scar therapy?

Embrace scar therapy is an FDA-cleared medical device that uses tension-offloading technology to reduce hypertrophic (raised, thickened) scars following surgery.

The silicone-based dressing is applied to closed surgical incisions where it mechanically offloads skin tension at the wound site during the critical healing and remodeling phases – typically weeks 2-12 post-operation.

Unlike passive silicone gels or sheets that rely on hydration alone, Embrace actively reduces mechanical tension on the wound, which is the primary driver of excessive collagen deposition and abnormal scar formation. This distinction makes it particularly valuable for high-tension surgical sites (abdominoplasty, facelift, breast surgery) where hypertrophic scarring is most likely.

The science of tension offloading

Hypertrophic scars develop when wound tension triggers excessive fibroblast activity and collagen cross-linking during healing. Studies show that reducing mechanical stress at the incision site leads to thinner, flatter scars with better color match and texture.

• Active tension relief: Embrace’s elastic properties continuously offload strain from the healing wound, mimicking the body’s natural scar maturation process.
• Collagen remodeling: Reduced tension suppresses excessive collagen deposition, allowing normal scar maturation to progress over weeks 2-12.
• Clinical outcome: Published RCT data shows statistically significant improvements on the Visual Analogue Scale (VAS, the trial’s primary endpoint) and the Patient and Observer Scar Assessment Scale (POSAS, its secondary endpoint) compared to standard post-operative care.

Clinical evidence: What the research says

A prospective randomized controlled trial published in Plastic and Reconstructive Surgery (2014) evaluated Embrace Advanced Scar Therapy versus standard wound care following abdominoplasty.

Its primary endpoint was the Visual Analogue Scale (VAS), scored from photographs at 6 and 12 months. Its secondary endpoint was the Patient and Observer Scar Assessment Scale (POSAS), scored at 7, 9, 11, and 13 weeks and again at 6 and 12 months. The Vancouver Scar Scale was not used in this trial.

Results showed statistically significant improvement on both endpoints. Investigator-rated POSAS scores favored the treated side on pigmentation, pliability, relief (roughness), vascularity, and overall opinion.

The 12-week protocol reflects the typical scar maturation window. Most clinicians observe visible improvement within 8-12 weeks of continuous wear, with further refinement possible up to 12-18 months post-surgery via natural remodeling.

Embrace product variants: Active Scar Defense vs. Minimize

Embrace offers two distinct product lines for different clinical scenarios.

Active Scar Defense is the evidence-backed choice for primary prevention in high-risk surgical sites. Minimize may help improve the appearance of older scars but should not be positioned with the same level of clinical certainty as Active Scar Defense.

Patient selection criteria

Ideal candidates are patients undergoing surgery with predictable high-tension wound closure or known genetic predisposition to hypertrophic scarring, a common consideration for plastic surgery practices.

• High-tension surgical sites: Abdominoplasty, facelift, breast reconstruction, burn repair, traumatic laceration closure.
• Skin types IV-VI (darker skin tones): Higher baseline risk of keloid and hypertrophic scar formation. Clinical assessment is recommended before prescribing.
• Younger age / genetic predisposition: Patients with family history of abnormal scarring or prior hypertrophic scars benefit most.
• Exclusions: Active wound infection, full-thickness burns, scars >12 months old requiring Minimize (evidence limited).

When to start treatment after surgery

Timing is critical for maximal efficacy. Apply Embrace only after the surgical wound is fully closed with no drainage or dehiscence risk.

1. Weeks 0-2: Wound still healing, with sutures or staples in place. Do not apply Embrace yet.
2. Weeks 2-4: Sutures removed, and the incision is fully sealed. This is the optimal window to start Embrace Active Scar Defense.
3. Week 4 onwards: If Embrace not started by week 4, efficacy may be slightly reduced (but still beneficial).

Instruct patients to personalize their treatment plan based on post-operative wound checks. Late starters (week 6+) can still benefit from Embrace, since the remodeling window remains open for 12+ weeks.

Step-by-step application protocol for clinicians

Practices using automated clinical documentation and digital forms can standardize the Embrace application teaching via branded patient instruction sheets (like the downloadable template above). Ensure staff follow this sequence.

1. Skin preparation: Gently cleanse the incision with mild soap and water, then pat dry (do not rub). Allow 5-10 minutes for skin to fully dry before applying Embrace.
2. Dressing placement: Peel backing and center the Embrace dressing over the incision, ensuring full contact along the entire scar line. Press gently for 30 seconds to secure adhesion.
3. Wear schedule: Continuous wear for 12 weeks is ideal. Patients may remove for showering (pat dry immediately after) but should reapply promptly.
4. Dressing changes: Each single-use dressing lasts approximately 7-10 days. Remove it once the edges begin to lift, let the skin rest for 12-24 hours, then apply a fresh dressing in the same position without shifting or repositioning it.
5. Activity restrictions: No swimming, hot tubs, or prolonged water submersion during wear, though gentle activity is fine. Heavy exercise may disrupt adhesion, so advise patients to wait 4-6 weeks before resuming full intensity.

Integrating Embrace into your post-surgical care workflow

Practices that embed Embrace into their standard post-operative protocol, whether in dermatology practices or surgical centers, see higher patient compliance and measurable scar outcome improvements. Use structured patient records to document initial scar assessment, Embrace start date, and follow-up progress.

Pre-operative consultation templates should screen for hypertrophic scar risk. Post-operative follow-ups (weeks 2, 6, 12) give clinicians touchpoints to reinforce Embrace adherence and assess scar trajectory.

Use automated patient follow-ups to send reminder messages at week 2 (“start Embrace now”), week 6 (“midpoint check-in”), and week 12 (“final assessment”).

Documenting scar outcomes: Tracking patient progress

Standardized outcome measurement differentiates evidence-based practices from those relying on subjective impression. The Vancouver Scar Scale (VSS) is a widely used four-domain tool for tracking scar maturation in routine practice.

VSS is a separate instrument from the ones used in the Embrace RCT cited above, which measured outcomes with the Visual Analogue Scale (VAS) and the Patient and Observer Scar Assessment Scale (POSAS). VSS simply offers practices a practical, in-office option for their own ongoing scar tracking.

As a practical in-office cadence (distinct from the RCT’s own assessment schedule), consider documenting baseline VSS at week 2 (pre-Embrace), a midpoint check at week 6, and a final assessment at week 12. Progressive improvement across the four domains supports a picture of clinical progress. Measuring scar satisfaction via patient compliance tools ensures shared decision-making and reinforces adherence.

Conclusion

Embrace scar therapy is a clinically validated, tension-offloading medical device that significantly reduces hypertrophic scar formation when applied 2-4 weeks post-operatively.

Success depends on timely initiation, patient compliance with the 12-week wear protocol, and structured outcome tracking using tools like the Vancouver Scar Scale.

Practices that integrate Embrace into their standard post-surgical workflow, using digital forms to distribute branded patient instructions and systematic documentation to track scar progression, achieve the best results.

Pabau’s patient engagement and outcome-tracking features help practices operationalize evidence-based Embrace protocols consistently, improving post-surgical scar outcomes and patient satisfaction.

Ready to streamline post-surgical scar management in your practice? Book a demo to see how digital forms, automated follow-ups, and structured outcome documentation help practices deliver evidence-based Embrace protocols at scale.

Expert picks

Continue your research

Coordinating scar care after a skin graft? The 15101 billing guide covers documentation for split-thickness autografts, a common companion procedure to high-tension wound closures.

Treating patients with pigmentation concerns? The L80 coding guide helps practices document vitiligo alongside other post-surgical skin assessments.

Need signed consent before starting treatment? Use this consent for treatment template to document patient agreement before beginning the Embrace protocol.

Frequently asked questions